Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?
Chimeric Antigen Receptor (CAR) T-cell therapy has become a new therapeutic reality for refractory and relapsed leukemia patients and is also emerging as a potential therapeutic option in solid tumors. Viral vector-based CAR T-cells initially drove these successful efforts; however, high costs and c...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/9/6/1337 |
| _version_ | 1797566906847199232 |
|---|---|
| author | Chiara F. Magnani Sarah Tettamanti Gaia Alberti Ilaria Pisani Andrea Biondi Marta Serafini Giuseppe Gaipa |
| author_facet | Chiara F. Magnani Sarah Tettamanti Gaia Alberti Ilaria Pisani Andrea Biondi Marta Serafini Giuseppe Gaipa |
| author_sort | Chiara F. Magnani |
| collection | DOAJ |
| description | Chimeric Antigen Receptor (CAR) T-cell therapy has become a new therapeutic reality for refractory and relapsed leukemia patients and is also emerging as a potential therapeutic option in solid tumors. Viral vector-based CAR T-cells initially drove these successful efforts; however, high costs and cumbersome manufacturing processes have limited the widespread clinical implementation of CAR T-cell therapy. Here we will discuss the state of the art of the transposon-based gene transfer and its application in CAR T immunotherapy, specifically focusing on the Sleeping Beauty (SB) transposon system, as a valid cost-effective and safe option as compared to the viral vector-based systems. A general overview of SB transposon system applications will be provided, with an update of major developments, current clinical trials achievements and future perspectives exploiting SB for CAR T-cell engineering. After the first clinical successes achieved in the context of B-cell neoplasms, we are now facing a new era and it is paramount to advance gene transfer technology to fully exploit the potential of CAR T-cells towards next-generation immunotherapy. |
| first_indexed | 2024-03-10T19:34:03Z |
| format | Article |
| id | doaj.art-c3c75952a1914ec19fe9141e59331da4 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T19:34:03Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-c3c75952a1914ec19fe9141e59331da42023-11-20T01:54:36ZengMDPI AGCells2073-44092020-05-0196133710.3390/cells9061337Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?Chiara F. Magnani0Sarah Tettamanti1Gaia Alberti2Ilaria Pisani3Andrea Biondi4Marta Serafini5Giuseppe Gaipa6Centro Ricerca M. Tettamanti, Clinica Pediatrica, Università di Milano-Bicocca, Ospedale San Gerardo, 20900 Monza, ItalyCentro Ricerca M. Tettamanti, Clinica Pediatrica, Università di Milano-Bicocca, Ospedale San Gerardo, 20900 Monza, ItalyCentro Ricerca M. Tettamanti, Clinica Pediatrica, Università di Milano-Bicocca, Ospedale San Gerardo, 20900 Monza, ItalyCentro Ricerca M. Tettamanti, Clinica Pediatrica, Università di Milano-Bicocca, Ospedale San Gerardo, 20900 Monza, ItalyCentro Ricerca M. Tettamanti, Clinica Pediatrica, Università di Milano-Bicocca, Ospedale San Gerardo, 20900 Monza, ItalyCentro Ricerca M. Tettamanti, Clinica Pediatrica, Università di Milano-Bicocca, Ospedale San Gerardo, 20900 Monza, ItalyCentro Ricerca M. Tettamanti, Clinica Pediatrica, Università di Milano-Bicocca, Ospedale San Gerardo, 20900 Monza, ItalyChimeric Antigen Receptor (CAR) T-cell therapy has become a new therapeutic reality for refractory and relapsed leukemia patients and is also emerging as a potential therapeutic option in solid tumors. Viral vector-based CAR T-cells initially drove these successful efforts; however, high costs and cumbersome manufacturing processes have limited the widespread clinical implementation of CAR T-cell therapy. Here we will discuss the state of the art of the transposon-based gene transfer and its application in CAR T immunotherapy, specifically focusing on the Sleeping Beauty (SB) transposon system, as a valid cost-effective and safe option as compared to the viral vector-based systems. A general overview of SB transposon system applications will be provided, with an update of major developments, current clinical trials achievements and future perspectives exploiting SB for CAR T-cell engineering. After the first clinical successes achieved in the context of B-cell neoplasms, we are now facing a new era and it is paramount to advance gene transfer technology to fully exploit the potential of CAR T-cells towards next-generation immunotherapy.https://www.mdpi.com/2073-4409/9/6/1337CAR T-cellssleeping beautytransposonacute leukemiagene transferimmunotherapy |
| spellingShingle | Chiara F. Magnani Sarah Tettamanti Gaia Alberti Ilaria Pisani Andrea Biondi Marta Serafini Giuseppe Gaipa Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going? Cells CAR T-cells sleeping beauty transposon acute leukemia gene transfer immunotherapy |
| title | Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going? |
| title_full | Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going? |
| title_fullStr | Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going? |
| title_full_unstemmed | Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going? |
| title_short | Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going? |
| title_sort | transposon based car t cells in acute leukemias where are we going |
| topic | CAR T-cells sleeping beauty transposon acute leukemia gene transfer immunotherapy |
| url | https://www.mdpi.com/2073-4409/9/6/1337 |
| work_keys_str_mv | AT chiarafmagnani transposonbasedcartcellsinacuteleukemiaswherearewegoing AT sarahtettamanti transposonbasedcartcellsinacuteleukemiaswherearewegoing AT gaiaalberti transposonbasedcartcellsinacuteleukemiaswherearewegoing AT ilariapisani transposonbasedcartcellsinacuteleukemiaswherearewegoing AT andreabiondi transposonbasedcartcellsinacuteleukemiaswherearewegoing AT martaserafini transposonbasedcartcellsinacuteleukemiaswherearewegoing AT giuseppegaipa transposonbasedcartcellsinacuteleukemiaswherearewegoing |